Novo Holdings completes Catalent acquisition for $16.5bn

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction.

The European Commission (EC) gave its approval in early December 2024.

Catalent’s common stock will no longer be listed on the New York Stock Exchange.

Catalent common stockholders will obtain $63.50 per share in cash. This reflects a 47.5% premium over the stock’s 60-day volume-weighted average price as of 2 February 2024.

The company aims to enhance its status as a global service provider for the pharmaceutical and biotechnology sectors while operating under private ownership.

Catalent president and CEO Alessandro Maselli will continue to lead the company following the acquisition.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

View profiles in store

Company Profile – free sample

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Novo Holdings CEO Kasim Kutay stated: “We are pleased to welcome Alessandro and the talented Catalent team to the Novo Holdings family.

“Catalent plays a key role in driving product development, launch and supply solutions for pharma, biotechnology and consumer health companies, and its mission is closely aligned with Novo Holdings’ purpose to invest for the benefit of people and the planet.”

In a strategic follow-up to the acquisition, Novo Nordisk also purchased three of Catalent’s fill-finish facilities from Novo Holdings. They are located in Bloomington in the US state of Indiana, Brussels, Belgium and Anagni, Italy along with related assets from Novo Holdings.

The deal for the manufacturing sites was initially announced in February.

For Catalent, Citi and JP Morgan acted as financial advisors.

Skadden, Arps, Slate, Meagher & Flom, and Jones Day served as legal advisors to Catalent and the company’s board of directors respectively.

Novo Holdings was advised by Morgan Stanley & Co. Legal advisory services for the company were provided by Goodwin Procter and Linklaters, and Arnold was legal advisor to Novo Nordisk.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.